Publication:
Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: A prospective, randomized, multicenter study

Simple item page
dc.contributor.authorKORTEN, VOLKAN
dc.contributor.authorsErman, M; Akova, M; Akan, H; Korten, V; Ferhanoglu, B; Koksal, I; Cetinkaya, Y; Uzun, O; Unal, S
dc.date.accessioned2022-03-12T17:16:16Z
dc.date.available2022-03-12T17:16:16Z
dc.date.issued2001
dc.description.abstractA total of 208 adult patients with cancer and febrile neutropenia from 5 medical institutions were randomized to receive either cefepime (2 g b.i.d.) or ceftazidime (2 g t.i.d.) in combination with amikacin (15 mg/kg/o.d.). Ninety-seven patients in the ceftazidime (CEZ) group and 98 in the cefepime group (CEF) were evaluable for efficacy. In 68 patients (35%), infection could be documented. The average duration of antibiotic therapy was 11 and 12 d and response rates to the empirical regimen were 36 and 30% for the CEZ and CEF groups, respectively (p>0.05). The average time of defervescence in responders was 3 d for both groups. Modification of the initial regimen with antivirals and/or azole antifungals raised the number of responders to 44% and 35%, respectively (p>0.05). Vancomycin was additionally given to 29 patients in the CEZ group and to 27 patients in the CEF group. Twenty-six patients in each group received empirical amphotericin B. Mild, reversible study drug-related side-effects were observed in 12 patients (12%) in the CEZ group and 13 patients (13%) in the CEF group (p>0.05). Cefepime in combination with amikacin seems to be as effective, safe and tolerable as ceftazidime + amikacin in patients with high-risk neutropenia and fever.
dc.identifier.doi10.1080/00365540110076679
dc.identifier.issn0036-5548
dc.identifier.pubmed11760163
dc.identifier.urihttps://hdl.handle.net/11424/227494
dc.identifier.wosWOS:000172095200008
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS AS
dc.relation.ispartofSCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCANCER-PATIENTS
dc.subjectFEVER
dc.subjectTHERAPY
dc.subjectMONOTHERAPY
dc.subjectTRIAL
dc.titleComparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: A prospective, randomized, multicenter study
dc.typearticle
dspace.entity.typePublication
local.avesis.idbf265435-fc44-4d02-8925-08613cb92268
local.import.packageSS17
local.indexed.atWOS
local.journal.numberofpages5
oaire.citation.endPage831
oaire.citation.issue11
oaire.citation.startPage827
oaire.citation.titleSCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
oaire.citation.volume33
relation.isAuthorOfPublication27f6afa3-0e46-45c9-a302-a6493c69bffb
relation.isAuthorOfPublication.latestForDiscovery27f6afa3-0e46-45c9-a302-a6493c69bffb

Files

Collections

Research Outputs